CKD Bio

At a glance

CKD Bio filed 20 disclosures in the last 12 months, including 3 earnings. The most recent key filing was on Oct 30: Operating profit: loss widened (-₩1.5B → -₩6B). Revenue ₩29.3B, down 14% YoY.

Revenue for 2025 was ₩160B, down 6.8% on 2024. Operating margin was 2.3% against 6.4% a year earlier. Debt was 136% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩81.8B and operating loss of ₩6.7B.

The 2025 annual report lists 533 employees with an average tenure of 10 years and average pay of ₩69M, #623 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩104.4M each on average. It paid no cash dividend for 2025. (주)종근당홀딩스 and related parties held 39.16% at year end.

From the 2025 annual report

Staff: 533 (430 men, 103 women), of whom 15 on fixed-term contracts. Total pay for the year: ₩36.2B. Directors and auditors: 5, paid ₩522M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)종근당홀딩스 holds 39.11%; with 1 related party the group holds 39.16% of common shares at year end.

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary